These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 36158638)

  • 1. Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy.
    Garcia-Pardo M; Czarnecka K; Law JH; Salvarrey A; Fernandes R; Fan J; Corke L; Waddell TK; Yasufuku K; Donahoe LL; Pierre A; Le LW; Ghumman N; Liu G; Shepherd FA; Bradbury P; Sacher A; Stockley T; Pal P; Rogalla P; Tsao MS; Leighl NB
    Ther Adv Med Oncol; 2022; 14():17588359221126151. PubMed ID: 36158638
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer: The ACCELERATE Nonrandomized Clinical Trial.
    García-Pardo M; Czarnecka-Kujawa K; Law JH; Salvarrey AM; Fernandes R; Fan ZJ; Waddell TK; Yasufuku K; Liu G; Donahoe LL; Pierre A; Le LW; Gunasegaran T; Ghumman N; Shepherd FA; Bradbury PA; Sacher AG; Schmid S; Corke L; Feng J; Stockley T; Pal P; Rogalla P; Pipinikas C; Howarth K; Ambasager B; Mezquita L; Tsao MS; Leighl NB
    JAMA Netw Open; 2023 Jul; 6(7):e2325332. PubMed ID: 37490292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complementing Tissue Testing With Plasma Mutation Profiling Improves Therapeutic Decision-Making for Patients With Lung Cancer.
    Choudhury Y; Tan MH; Shi JL; Tee A; Ngeow KC; Poh J; Goh RR; Mong J
    Front Med (Lausanne); 2022; 9():758464. PubMed ID: 35223889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot of Blood-First diagnostic cell free DNA (cfDNA) next generation sequencing (NGS) in patients with suspected advanced lung cancer.
    Cui W; Milner-Watts C; McVeigh TP; Minchom A; Bholse J; Davidson M; Yousaf N; MacMahon S; Mugalaasi H; Gunapala R; Lee R; George A; Popat S; O'Brien M
    Lung Cancer; 2022 Mar; 165():34-42. PubMed ID: 35085982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimizing Mutation and Fusion Detection in NSCLC by Sequential DNA and RNA Sequencing.
    Cohen D; Hondelink LM; Solleveld-Westerink N; Uljee SM; Ruano D; Cleton-Jansen AM; von der Thüsen JH; Ramai SRS; Postmus PE; Graadt van Roggen JF; Hoppe BPC; Clahsen PC; Maas KW; Ahsmann EJM; Ten Heuvel A; Smedts F; van Rossem RN; van Wezel T
    J Thorac Oncol; 2020 Jun; 15(6):1000-1014. PubMed ID: 32014610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health system.
    Yang CY; Shih JY; Liao WY; Ho CC; Hsu CL; Tsai TH; Wu SG; Lin YT; Hsu WH; Jain S; Olsen S; Yang JC; Yu CJ; Yang PC
    Eur J Cancer; 2023 Nov; 193():113310. PubMed ID: 37722270
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liquid First Is "Solid" in Naïve Non-Small Cell Lung Cancer Patients: Faster Turnaround Time With High Concordance to Solid Next-Generation Sequencing.
    Sehayek O; Kian W; Onn A; Stoff R; Sorotsky HG; Zemel M; Bar J; Dudnik Y; Nechushtan H; Rottenberg Y; Soussan-Gutman L; Dvir A; Roisman LC; Peled N
    Front Oncol; 2022; 12():912801. PubMed ID: 35785173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC-Results From a Prospective Pilot Study.
    Thompson JC; Aggarwal C; Wong J; Nimgaonkar V; Hwang WT; Andronov M; Dibardino DM; Hutchinson CT; Ma KC; Lanfranco A; Moon E; Haas AR; Singh AP; Ciunci CA; Marmarelis M; D'Avella C; Cohen JV; Bauml JM; Cohen RB; Langer CJ; Vachani A; Carpenter EL
    JTO Clin Res Rep; 2022 Apr; 3(4):100301. PubMed ID: 35392653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
    Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
    Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CONCORDANCE: A real-world evidence study to evaluate the concordance of detecting epidermal growth factor receptor (EGFR) mutation by circulating tumor DNA* versus tissue biopsy in patients with metastatic non-small cell lung cancer.
    Prabhash K; Biswas B; Khurana S; Batra U; Biswas G; Advani SH; Mohapatra PN; Rajappa S; Sharma A; Patil S; Dattatreya PS; Roy R; Almel S; Goyal G; Warrier N
    Indian J Cancer; 2022 Mar; 59(Supplement):S11-S18. PubMed ID: 35343188
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expediting Comprehensive Molecular Analysis to Optimize Initial Treatment of Lung Cancer Patients With Minimal Smoking History.
    Dagogo-Jack I; Robinson H; Mino-Kenudson M; Farago AF; Kamesan V; Iafrate AJ; Shaw AT; Lennerz JK
    J Thorac Oncol; 2019 May; 14(5):835-843. PubMed ID: 30660796
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical utility of next-generation sequencing-based ctDNA testing for common and novel ALK fusions.
    Mondaca S; Lebow ES; Namakydoust A; Razavi P; Reis-Filho JS; Shen R; Offin M; Tu HY; Murciano-Goroff Y; Xu C; Makhnin A; Martinez A; Pavlakis N; Clarke S; Itchins M; Lee A; Rimner A; Gomez D; Rocco G; Chaft JE; Riely GJ; Rudin CM; Jones DR; Li M; Shaffer T; Hosseini SA; Bertucci C; Lim LP; Drilon A; Berger MF; Benayed R; Arcila ME; Isbell JM; Li BT
    Lung Cancer; 2021 Sep; 159():66-73. PubMed ID: 34311346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and clinical validation of a circulating tumor DNA test for the identification of clinically actionable mutations in nonsmall cell lung cancer.
    Liu L; Liu H; Shao D; Liu Z; Wang J; Deng Q; Tang H; Yang H; Zhang Y; Qiu Y; Cui F; Tan M; Zhang P; Li Z; Liu J; Liang W; Wang Y; Peng Z; Wang J; Yang H; Mao M; Kristiansen K; Ye M; He J
    Genes Chromosomes Cancer; 2018 Apr; 57(4):211-220. PubMed ID: 29277949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC.
    Cheng ML; Milan MSD; Tamen RM; Bertram AA; Michael KS; Ricciuti B; Kehl KL; Awad MM; Sholl LM; Paweletz CP; Jänne PA
    JCO Precis Oncol; 2021 Nov; 5():726-732. PubMed ID: 34994618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients.
    Francaviglia I; Magliacane G; Lazzari C; Grassini G; Brunetto E; Dal Cin E; Girlando S; Medicina D; Smart CE; Bulotta A; Gregorc V; Pecciarini L; Doglioni C; Cangi MG
    Lung Cancer; 2019 Aug; 134():225-232. PubMed ID: 31319985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients.
    Cui W; Milner-Watts C; O'Sullivan H; Lyons H; Minchom A; Bhosle J; Davidson M; Yousaf N; Scott S; Faull I; Kushnir M; Nagy R; O'Brien M; Popat S
    Eur J Cancer; 2022 Aug; 171():44-54. PubMed ID: 35704974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities.
    Gutierrez ME; Choi K; Lanman RB; Licitra EJ; Skrzypczak SM; Pe Benito R; Wu T; Arunajadai S; Kaur S; Harper H; Pecora AL; Schultz EV; Goldberg SL
    Clin Lung Cancer; 2017 Nov; 18(6):651-659. PubMed ID: 28479369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice.
    Cho BC; Loong HHF; Tsai CM; Teo MLP; Kim HR; Lim SM; Jain S; Olsen S; Park K
    Curr Oncol; 2022 Mar; 29(3):2154-2164. PubMed ID: 35323374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.